Literature DB >> 1871509

Tumor markers in human renal cell carcinoma.

K Kusama1, M Asano, I Moro, T Sekine, T Kakizoe, K Tobisu, K Kishi.   

Abstract

Localization of tumor markers in human renal cell carcinomas (RCC) was studied by an immunohistochemical method using 12 different monoclonal antibodies (MAbs) recognizing carbohydrate antigens, and 2 polyclonal antibodies against S-100 protein and neuron-specific enolase (NSE), respectively. 115D8, DF3 and the MAb to epithelial membrane antigen (EMA) reacted with 9 of 13 (115D8), 6 of 13 (DF3) and 5 of 12 (MAb to EMA) cases of RCC, respectively. S-100 protein was also found in 10 of 13 cases of RCC. Further immunohistochemical studies showed that tumor cells of all 13 RCCs were strongly positive for NSE. Serum NSE levels of patients with RCC were examined by radioimmunoassay. This examination revealed that increased levels of NSE were detected in 11 of 17 sera of patients with RCC. Positive rates for patients in stages II, III and IV were 100% (10/10). On the other hand, increased levels of CA15-3 were detected in only 2 of 17 sera by enzyme immunoassay. Our results indicate that NSE may be a useful marker for human RCC, especially for those tumors that have broken through the renal capsule.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871509     DOI: 10.1159/000217704

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  2 in total

Review 1.  Clear cell carcinoma of the breast with solid papillary pattern: a case report with immunohistochemical profile.

Authors:  Y Gürbüz; S K Ozkara
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

2.  Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report.

Authors:  Yojiro Ishikawa; Rei Umezawa; Takaya Yamamoto; Noriyoshi Takahashi; Kazuya Takeda; Yu Suzuki; Keiichi Jingu
Journal:  J Med Case Rep       Date:  2022-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.